Ultravate

Quick links to important sections

Ultravate

Selected form

Method of action: Very Strong

Treatment option: Plaque Psoriasis, Psoriasis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ultravate

Quick Facts

Property Description
Active ingredient Halobetasol propionate (Ulobetasol propionate)
Form Topical preparations (Cream, Ointment, Lotion, Foam)
Pharmacological class Corticosteroids (Glucocorticoid)
Common purpose Relief of inflammation and itching
Origin Synthetic (Fluorinated derivative)

What Type of Medicine is Ultravate?

Ultravate is a prescription-only topical medication containing the active ingredient halobetasol propionate, which is a powerful, synthetic corticosteroid. This compound belongs to the broader glucocorticoid pharmacological class, utilized primarily for its effects on the skin. Halobetasol propionate is characterized by its classification as a super-high potency topical steroid.

This high strength is a key differentiating factor, placing it among the most potent agents available, unlike common over-the-counter options. The compound is a fluorinated derivative, a structural feature that supports its significantly increased effectiveness. This formulation is approved for topical use, confirming its potent anti-inflammatory properties.

Composition and Available Topical Forms

The medication's effect is driven by the single active ingredient, halobetasol propionate, also known by the INN Ulobetasol propionate. It is formulated exclusively for topical administration and is available in several dosage forms, including a cream, ointment, lotion, and aerosol foam.

The variety of preparations, which include vehicles like the moisturizing ointment base or the lighter lotion base, allows medical professionals to select the optimal consistency based on the treated body area and the nature of the dermatosis. This choice ensures targeted delivery of the active compound.

General Purpose of Halobetasol Propionate

The overall purpose of halobetasol propionate is to provide intensive and rapid symptomatic relief for highly inflammatory skin conditions. It achieves this by producing a strong anti-inflammatory effect to diminish swelling and redness, along with a powerful antipruritic effect to suppress severe and persistent itching. The medication’s super-high potency is employed to quickly bring significant, treatment-resistant skin inflammation under control.

Regulatory References

  1. Halobetasol Topical Drug Information

What side effects are possible with Ultravate?

Possible Side Effects and Safety Information

The safety profile for Ultravate (halobetasol propionate) is determined by its classification as a super-high potency topical corticosteroid. Adverse reactions are grouped into expected local effects and risks associated with systemic absorption, which can occur due to the drug's high strength.


Documented Adverse Reactions

Adverse effects are primarily observed at the application site or within specific physiological systems upon systemic uptake. The most frequently documented reactions are associated with the skin:

Classification Adverse Reaction (Skin and Subcutaneous Tissue)
Common (Reported in ge 1% of patients) Burning, Stinging
Less Common/Infrequent Pruritus (Itching), Erythema (Redness), Skin Atrophy, Folliculitis, Telangiectasia

Systemic Risks and Serious Adverse Reactions

Due to the potential for systemic absorption, the official safety documentation includes risks involving the Endocrine and Ophthalmic systems:

  • Endocrine System: Serious adverse reactions include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's Syndrome. These conditions reflect the body's response to absorbed corticosteroid.
  • Ophthalmic System: Potential risks include the development of glaucoma or posterior subcapsular cataracts, often associated with prolonged use.

Population and Exposure Safety Patterns

Regulatory documents emphasize that the risk of systemic effects, such as HPA axis suppression, is increased with prolonged use, application to large surface areas, and the use of occlusive dressings.

Pediatric Safety: Children, particularly those under 12 years of age, are at a greater risk of HPA axis suppression and Cushing's Syndrome due to their increased skin surface area-to-body weight ratio. Use in this population is generally not recommended or established. The medication is also restricted from high-absorption areas like the face, groin, or axillae.

Overdose and Emergency Response

Overdose and When to Seek Help

If overdosage of Ultravate (halobetasol propionate) is suspected, regulatory guidance states that it is required to contact a poison control center or emergency room at once.

Overdosage typically results from the potential for systemic absorption following prolonged application, use over large body surface areas, or application under occlusive dressings. This excessive exposure may lead to reversible suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which is the primary physiological finding in overdose.

Documented Systemic Manifestations:

  • Cushing’s Syndrome Manifestations: Clinical signs associated with excessive glucocorticoid exposure.
  • Metabolic Changes: Laboratory findings of hyperglycemia and glucosuria.

Severe Outcomes and Management: The principal severe outcome is the risk of glucocorticosteroid insufficiency, particularly upon discontinuation of the drug. A severe complication, adrenal insufficiency, may require treatment with supplemental systemic corticosteroids. Management of HPA axis suppression involves attempts to withdraw the product, reduce the frequency of application, or substitute a less potent corticosteroid. Periodic evaluation for HPA axis function is required for patients at high risk of systemic exposure.

Population-Specific Consideration: Pediatric patients are identified as having a greater vulnerability to HPA axis suppression and Cushing's syndrome due to their increased body surface area to mass ratio.

Therapeutic Uses of Ultravate

Quick Facts

  • Primary Use: Management of plaque psoriasis.
  • Secondary Uses: Provides relief for inflammatory and pruritic skin conditions that respond to topical corticosteroids.
  • Goal of Therapy: Supports the reduction of swelling, redness, and itching associated with skin conditions.

Ultravate (halobetasol propionate) is a prescribed topical medication used for the management of certain dermatological conditions. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

The primary approved therapeutic domain for this medication is the topical treatment of plaque psoriasis in adult patients and certain children. Plaque psoriasis is a condition characterized by scaly, inflamed, and sometimes itchy patches on the skin. Use of Ultravate helps to alleviate the associated discomfort.

Beyond psoriasis, this drug may also be used as part of a treatment plan to address other skin conditions where inflammation, redness, and itching are present, provided they are determined by a physician to be corticosteroid-responsive. The ultimate aim of therapy is to achieve control over the symptoms experienced by the patient.

Eligibility and Restrictions for Use

Ultravate (halobetasol propionate) is a super-high potency topical medicine with explicit eligibility rules defined by regulatory agencies.

Contraindications and Non-Eligible Populations

Ultravate is contraindicated for patients with a known hypersensitivity to halobetasol propionate or any component of the formulation. It is prohibited for use in treating rosacea or perioral dermatitis.

Age and Physiological Status

Population Eligibility Status (Regulatory Labeling)
Adults Eligible for standard labeled conditions.
Children 12 and older Eligible for treatment, as safety and effectiveness have been established.
Children under 12 Use is not recommended; safety and effectiveness have not been established.
Pregnant Women Use is permitted only if the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).
Breastfeeding Women Caution is recommended during use.

Conditional Use Restrictions

Use is highly restricted due to the drug's potency. Treatment must not exceed two consecutive weeks. Application must be avoided on sensitive areas, including the face, groin, and axillae. Additionally, the medicine must not be used with occlusive dressings (such as bandages) unless specifically directed by a physician. Patients with liver failure may be predisposed to an increased risk of systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Ultravate (halobetasol propionate) primarily documents a risk related to additive systemic exposure rather than typical pharmacokinetic drug-drug interactions.

Documented Interaction Patterns

The primary concern identified in official prescribing information is the pharmacodynamic risk associated with the concomitant use of multiple corticosteroid-containing products. This includes using other topical corticosteroids or systemic (oral) corticosteroids concurrently with Ultravate.

This co-administration is officially documented as a factor that may increase the total systemic exposure to the active ingredient, halobetasol propionate, thereby increasing the potential for systemic effects, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Interaction Type Official Regulatory Finding
Pharmacodynamic Risk Increased systemic exposure risk with other corticosteroid-containing products.
Metabolic (CYP) / Transporter No known significant interactions explicitly documented in regulatory labels.
Contraindicated Combinations None explicitly listed due to drug-drug interaction risk.

Substance and Population Considerations

Official regulatory documents do not define any formal interactions with food, alcohol, supplements, or herbal products. Furthermore, the label does not specify any mandatory timing separation requirements for co-administering substances. A population-specific note highlights that young age is a factor that predisposes patients to the systemic effects of increased exposure due to a higher skin surface area to body mass ratio.

Mechanism of Action

How Ultravate Works

Ultravate (halobetasol propionate) is a synthetic topical corticosteroid that works through several key mechanistic pathways to modulate local physiological responses.

Glucocorticoid Receptor Binding and Gene Modulation

Ultravate's action is initiated by binding to intracellular glucocorticoid receptors within skin cells. The resulting steroid-receptor complex then moves into the cell nucleus, where it modulates the transcription of specific genes. This genomic pathway increases the synthesis of anti-inflammatory proteins while simultaneously suppressing the production of various pro-inflammatory mediators, resulting in transcriptional changes that modify pathway signaling.


Inhibition of Inflammatory Mediators

A key cascade effect involves the induction of proteins like lipocortin (or Annexin A1), which inhibit the enzyme phospholipase A2. This blockade prevents the release of arachidonic acid, a critical precursor molecule. By limiting arachidonic acid, the drug suppresses the biosynthesis of potent inflammation mediators, such as prostaglandins and leukotrienes.


Vasoconstriction and Capillary Permeability

Ultravate also exhibits direct effects on the local vasculature, engaging mechanisms that lead to vasoconstriction (narrowing of blood vessels). This action decreases capillary permeability, which limits the leakage of fluids and cells into the tissue space.


️ Immune Cell Activity Suppression

The drug's mechanism includes modulating the activity and migration of key immune cells, such as T-lymphocytes and macrophages. This action dampens the functional response and movement of these immune cells within the tissue.

Dosage and Administration Information

How to Use Ultravate (Halobetasol Propionate)

The usage of Ultravate is governed by specific instructions to ensure appropriate topical application of this high-potency corticosteroid. The medication is indicated strictly for topical use and must not be used for ophthalmic, oral, or intravaginal administration. For all 0.05% formulations (cream, ointment, lotion, and foam), a thin layer is to be applied to the affected area and rubbed in gently.


Dosing and Time Constraints

The usage protocol is strictly time-limited and dosage-constrained.

Usage Constraint Detail
Frequency Cream/Ointment: Once or twice daily. Lotion/Foam: Twice daily.
Maximum Dose Should not exceed 50 grams (or 50 mL) per week.
Duration Limit Treatment is generally limited to two consecutive weeks. Therapy should be discontinued once control is achieved.

Procedural and Age-Specific Rules

The 0.05% formulations are not recommended for use in children under the age of 12. For the topical foam, the can requires shaking prior to use.

Certain areas of the body, including the face, groin, and axillae (underarms), must be avoided during application. Additionally, the treated skin area should not be covered or wrapped with occlusive dressings (such as bandages) unless specifically directed by a healthcare professional. If no improvement is observed after two weeks, the diagnosis should be reassessed.

Recent Clinical Evidence

Research Evidence Overview for Ultravate (Halobetasol Propionate)

Evidence Base for Plaque Psoriasis

The primary research for Ultravate was conducted using randomized, double-blind, vehicle-controlled clinical trials (RCTs), which are considered a high standard for evaluating new medicines. These studies were used in research exploring how symptoms change over time in adults who had plaque psoriasis. In these trials, researchers examined the effect of the medication compared to an inactive base, known as the vehicle.

The main measure used to evaluate the medicine was observed in outcomes related to physical discomfort, specifically through the Investigator Global Assessment (IGA) score. This score was used to categorize the severity of the condition and determine whether a participant met the defined criteria for study endpoint achievement. These findings describe patterns observed in the studies where the percentage of participants meeting the defined criteria for study endpoint achievement differed between the groups using the active medication and the groups using the vehicle. Research also examined the status of individual symptoms, such as erythema (redness) and scaling.

However, the majority of the pivotal trials for the higher 0.05% concentration formulations were designed to assess outcomes over a short-term follow-up duration of only two consecutive weeks. This means that there is limited information for long-term outcomes or how the medication may perform over many months of use. The results apply only to the populations studied, which were typically adults with a moderate, but limited, extent of body surface involvement.


Evidence for Corticosteroid-Responsive Skin Conditions

Ultravate was studied for use in a broad group of conditions where symptoms may vary in intensity and which are known to respond to topical corticosteroids. The evidence related to this general indication involves studies that classify the medicine's potency. These pharmacological studies monitored the vasoconstrictor response (a measure of skin change) and reported findings that consistently placed halobetasol propionate in the highest potency range.

The regulatory review utilizes this high potency classification to define the scope of use for outcomes linked to inflammatory or irritative states and general physical discomfort. The research describes that observations across responsive dermatoses aligned with the patterns associated with this class of drug.

It is important to understand that the comparative evidence is lacking for many specific, individual dermatoses within this broad category. Instead of dedicated RCTs for every condition, the evidence structure relies on the demonstrated potency of the active ingredient and the findings from the main plaque psoriasis trials. The follow-up durations were limited to short intervals, which reflects the standards for studying agents of this high potency class.


Research Gaps and Unanswered Questions

The evidence highlights what is known—and what is still uncertain—about this medicine. The primary limitation is that follow-up durations were limited for the highest-concentration formulation (0.05%). This limited data means that the potential long-term course of treatment or the likelihood of systemic effects with extended use are areas where certainty remains low. Comparative evidence is lacking between Ultravate and other similar active medications used for skin conditions. Finally, research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Ultravate (FAQ)


Q: Is Ultravate the same as other steroid creams I've used before?

According to official product information, Ultravate (halobetasol propionate) is classified as a super-high potency topical corticosteroid. This high-potency ranking differentiates it from many other topical steroid creams available, including over-the-counter options. The potent classification is a key factor considered by healthcare providers when determining its use.


Q: What happens if Ultravate accidentally gets into the eyes?

Regulatory documents state that use of this medicine must avoid contact with the eyes entirely, as the medication is approved strictly for topical skin use. If accidental contact does occur, official guidance recommends rinsing the eyes out with plenty of cool tap water.


Q: Can Ultravate be used on large areas of the body?

Official warnings note that applying this medication over large surface areas of the body is a factor that can increase the risk of systemic effects. Systemic effects occur when the medicine is absorbed into the bloodstream. For this reason, official labeling emphasizes strict limits on the amount and duration of use.


Q: Do studies suggest that Ultravate can affect blood sugar levels?

When systemic absorption occurs, regulatory documents list potential serious adverse reactions including hyperglycemia (high blood sugar) and glucosuria (sugar in the urine). These effects reflect the body's response to absorbed corticosteroids, which is a potential risk associated with the use of high-potency topical agents.


Q: Are there any common misuses of Ultravate mentioned in patient education materials?

Patient education materials emphasize the importance of using the medication strictly as prescribed. Patients are advised not to use the medication for any disorder other than that for which it was prescribed, which helps prevent potential use for skin disorders other than those specifically approved.


Q: What skin conditions is Ultravate generally approved to treat?

Ultravate is indicated for the relief of inflammatory and itchy symptoms (pruritic manifestations) of corticosteroid-responsive dermatoses. This broad category includes conditions like plaque psoriasis. Its potent anti-inflammatory properties are utilized in an attempt to bring significant skin inflammation under control.


Q: How quickly should someone expect Ultravate to start working?

Official patient information indicates that most patients start to see an improvement in their skin condition within a few days of beginning treatment. The potent nature of the active ingredient is intended to provide rapid symptomatic relief for highly inflammatory skin issues.


Q: If I miss an application of Ultravate, what should I generally do?

If a dose is missed, patient instructions generally describe applying the missed dose as soon as it is remembered. However, it is typically noted that if it is almost time for the next scheduled dose, the missed dose should be skipped to resume the regular schedule, without applying two doses.


Q: Is Ultravate safe for people over 65?

The medication has not been extensively studied in geriatric populations. Official documents contain a note of caution for use in people over 65 because the skin of elderly individuals may be more susceptible to increased systemic absorption and fragility, which are factors considered during treatment assessment.


Q: Is there a generic version of Ultravate available?

Yes, halobetasol propionate is the name of the generic medication that is the active ingredient in the brand-name product Ultravate. The generic forms contain the same active ingredient and are approved by the FDA.


Q: Does Ultravate have a withdrawal period described in official documents?

Due to the potent nature of this medication, abruptly stopping treatment may potentially complicate symptoms of adrenal insufficiency. Official guidance documents suggest a gradual reduction of the amount or frequency of application over time may be necessary before completely discontinuing use.


Q: Does Ultravate contain parabens or other preservatives people often ask about?

Official drug monographs confirm that some of the formulations, such as the lotion, may contain preservatives like butylparaben and propylparaben. The specific inactive ingredients vary depending on the preparation (cream, ointment, or foam), and can be confirmed in the full prescribing information for the specific product used.


Q: Can Ultravate cause changes in skin pigmentation?

Official adverse reaction lists note that changes in skin color, also known as hypopigmentation or leukoderma, are possible side effects that have been reported. This type of effect is important to monitor and discuss with a healthcare provider if observed.


Q: Are headaches a noted side effect of using topical Ultravate?

Yes, regulatory documents list headache as an adverse reaction that was reported in clinical trials involving the use of the topical medication. This type of effect reflects a potential systemic response to the medication.


Q: What are the recommendations regarding swimming or showering after applying Ultravate?

While the primary label does not typically specify an exact time to wait before swimming or showering, patient instructions recommend washing hands both before and after applying the medicine. Following application, the product is intended to absorb into the skin.


Q: Can Ultravate be used for fungal infections?

The medication is not indicated to treat infections; however, some regulatory labels contraindicate its use for untreated bacterial, tubercular, and fungal skin infections. Official prescribing information advises that if a concomitant skin infection is present, appropriate antifungal or antibacterial agents should be used to treat it.


Q: How is Ultravate absorbed into the body when applied to the skin?

Official pharmacokinetic information confirms that the topically applied medication can be absorbed through the skin in amounts sufficient to produce systemic effects. This process of absorption is influenced by factors such as the integrity of the skin barrier and the specific vehicle (cream, ointment, etc.) used in the formulation.


Q: Is it necessary to wash hands after applying Ultravate?

Patient safety instructions from regulatory sources note that washing hands both before and immediately after applying Ultravate is generally recommended. This is an important step unless the area being treated is the hands themselves.

How should Ultravate be stored and disposed of?

Storage and Disposal Requirements for Ultravate

Ultravate (halobetasol propionate) must be stored under specific environmental and container rules to maintain stability, as required by regulatory labeling.

Storage Conditions

Requirement Details
Temperature Store at controlled room temperature: 20^circ to 25 C (68^circ to 77 F).
Protection Keep away from heat, moisture, and direct light. Do not freeze the medicine.
Container Must be stored in a closed container and kept out of the reach of children.
Foam Handling The pressurized foam canister must not be punctured, incinerated, or exposed to temperatures above 120 F (49 C).

Disposal Instructions

Patients must ask a healthcare professional or pharmacist how to dispose of any unused or outdated Ultravate, as it should not be kept. The foam canister, due to flammability, must not be thrown into a fire.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ultravate found in:

A-Z Index: